Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401483 | 1.00 | MEN1 (0.45) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL1202215 | 1.00 | MEN1 (0.45) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL8994840 | 1.00 | MEN1 (0.45) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL1202221 | 1.00 | MEN1 (0.45) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL14617333 | 0.82 | MEN1 (0.42) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL21258202 | 0.82 | MEN1 (0.42) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL21237763 | 0.79 | MEN1 (0.49) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL8613489 | 0.78 | LMNA (0.44) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL4442210 | 0.78 | LMNA (0.44) | MEN1KMT2ACTDSP1ALDH1A1CYP3A4 | |
| SCHEMBL28860155 | 0.78 | MEN1 (0.33) | MEN1KMT2ACTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4532662-B1 | LAUNDRY LIQUID COMPOSITION COMPRISING A SURFACTANT, AN ALKOXYLATED ZWITTERIONIC POLYAMINE POLYMER, AND A FRAGRANCE | UNILEVER IP HOLDINGS B V (NL) | 2025-08-27 | — | — | EP | claimed |
| US-11364184-B2 | Perfume compositions | GIVAUDAN SA (CH) | 2022-06-21 | — | — | US | claimed |
| WO-2018145219-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING ADDICTIONS BY MEANS OF AVERSIVE COUNTERCONDITIONING | SERANI MOSTAZAL JORGE (CL) | 2018-08-16 | — | — | WO | claimed |
| US-9200237-B2 | 4,8-dimethyl-4,9-decadienenitrile | KAO CORPORATION (JP) | 2015-12-01 | — | — | US | claimed |
| WO-2011101181-A1 | PERFUME COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2011-08-25 | — | — | WO | claimed |
| EP-1948773-A1 | FRAGRANT CONSUMER PRODUCTS COMPRISING OXIDIZING AGENTS | Henkel AG & Co. KGaA (DE) | 2008-07-30 | — | — | EP | claimed |
| WO-2007054177-A1 | FRAGRANT CONSUMER PRODUCTS COMPRISING OXIDIZING AGENTS | HENKEL AG & CO. KGAA (DE) | 2007-05-18 | — | — | WO | claimed |
| US-5530164-A | Process for the production of trans-3,3,5-trimethylcyclohexyl ethyl ether | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1996-06-25 | — | — | US | claimed |
| EP-0549618-B1 | METHOD FOR THE PREPARATION OF TRANS-3,3,5-TRIMETHYLCYCLOHEXYL ETHYL ETHER | HENKEL KGAA (DE) | 1995-11-22 | — | — | EP | claimed |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2026-05-14 | — | — | US | disclosed |
| EP-4717756-A2 | LIPASE VARIANTS AND DETERGENT COMPOSITIONS | Novozymes A/S (DK) | 2026-04-01 | — | — | EP | disclosed |
| US-12559736-B2 | Lipase variants and polynucleotides encoding same | NOVOZYMES A/S (DK) | 2026-02-24 | — | — | US | disclosed |
| EP-4692252-A1 | FUNCTIONAL PARTICLE DISPERSION | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12529017-B2 | Detergent composition comprising a lipase | NOVOZYMES A/S (DK) | 2026-01-20 | — | — | US | disclosed |
| US-5530164-A | Process for the production of trans-3,3,5-trimethylcyclohexyl ethyl ether | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1996-06-25 | — | — | US | disclosed |
| US-5530164-A | Process for the production of trans-3,3,5-trimethylcyclohexyl ethyl ether | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1996-06-25 | — | — | US | disclosed |
| EP-0549618-B1 | METHOD FOR THE PREPARATION OF TRANS-3,3,5-TRIMETHYLCYCLOHEXYL ETHYL ETHER | HENKEL KGAA (DE) | 1995-11-22 | — | — | EP | disclosed |
| EP-0549618-A1 | METHOD FOR THE PREPARATION OF TRANS-3,3,5-TRIMETHYLCYCLOHEXYL ETHYL ETHER. | HENKEL KGAA (DE) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992005136-A1 | METHOD FOR THE PREPARATION OF TRANS-3,3,5-TRIMETHYLCYCLOHEXYL ETHYL ETHER | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1992-04-02 | — | — | WO | disclosed |
| WO-1992005136-A1 | METHOD FOR THE PREPARATION OF TRANS-3,3,5-TRIMETHYLCYCLOHEXYL ETHYL ETHER | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559736-B2 | Lipase variants and polynucleotides encoding same | LPL, PNLIP, LIPG | MEN1 4746/4885KMT2A 1702/4885CTDSP1 174/4885 |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | LIPE, LPL, PNLIP | MEN1 2500/4885KMT2A 2359/4885CTDSP1 922/4885 |
| US-12529017-B2 | Detergent composition comprising a lipase | MGLL, LPL, LIPC | MEN1 4834/4885KMT2A 3106/4885CTDSP1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.